Finally, Protagonist Therapeutics (NASDAQ:PTGX) has indicated that its financial runway extends beyond the fourth quarter of 2028, providing the company with a stable foundation to continue its ...

The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027 ...

Officer of Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a $2.2 billion market cap biotech company, recently reported the sale of 3,640 shares of common stock on January 16, 2025. The transactions ...

NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his ...

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a company overview at the 43rd ...

BTIG analyst Julian Harrison maintained a Hold rating on United Therapeutics (UTHR – Research Report) on January 21. The company’s shares ...

NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon ...

Protagonist Therapeutics, Inc. (PTGX) stock price is 36.54 and Protagonist Therapeutics, Inc. (PTGX) 10-day simple moving average is 37.76. Protagonist Therapeutics, Inc. (PTGX) stock price is 36. ...

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice ...